Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-07265807 |
| Synonyms | |
| Therapy Description |
PF-07265807 is a small molecule inhibitor of MERTK and AXL, which may modulate immune response and lead to anti-tumor activity (J Clin Oncol 39, 2021 (suppl 15; abstr TPS2671). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-07265807 | PF 07265807|PF07265807 | AXL Inhibitor 30 MERTK Inhibitor 13 | PF-07265807 is a small molecule inhibitor of MERTK and AXL, which may modulate immune response and lead to anti-tumor activity (J Clin Oncol 39, 2021 (suppl 15; abstr TPS2671). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04458259 | Phase I | PF-07265807 | A Study of PF-07265807 In Participants With Advanced or Metastatic Solid Tumors | Terminated | USA | ITA | ESP | CAN | 1 |